In this episode of IBD Drive Time, guest host David Rubin, MD, calls on Drs Severine Vermeire of KU Leuven University in Belgium and Dan Tucker of Hebrew University of Jerusalem to talk about the challenges of recruiting patients for clinical trials in inflammatory bowel disease and the ethical issues involved.

Dr Scott discusses the development of a pathway based on specific diagnostic criteria that indicate the need to refer patients with inflammatory bowel disease to specialist centers.

In the latest IBD Drive Time, host Raymond Cross, MD, talks with Ryan Stidham, MD, about potential applications for artificial intelligence and ChatGPT in gastroenterology practice—and what is feasible right now.

Drs Brian Lacy and Mark Pimentel provide an update on the progress in diagnosing and treating small intestinal bacterial overgrowth and a similar condition, intestinal methanogen overgrowth (IMO).

Dr Edward Loftus reviews details of the pivotal trial where upadacitinib emerged a superior alternative to placebo for induction and maintenance therapy among patients with moderate-to-severe Crohn’s disease.

In this podcast, Dr Adam Faye explains the association between various patient-level demographic, nutritional and clinical factors and risk for complications among older patients who underwent intestinal resection for inflammatory bowel disease.

--

Adam Faye, MD, is an assistant professor of medicine and population health at the Inflammatory Bowel Disease Center at NYU Langone Health.

--

Dr Gil Melmed from Cedars-Sinai talks with Drs Raymond Cross and Millie Long about the importance of vaccines, cancer screenings, and other aspects of overall health maintenance for patients with inflammatory bowel disease.

IBD Drive Time: Christina Ha, MD, on Biosimilars by Gastroenterology Learning Network

Guest Christina Ha, MD, from the Mayo Clinic in Arizona, reviews key points about the advent of biosimilars, including reassuring patients and countering the "nocebo" effect, with hosts Drs Raymond Cross and Millie Long.

The 2 leading gastrointestinal societies in United States—the American Gastroenterological Association and the American College of Gastroenterology—collaborated to produce guidance on pharmacological agents available for the treatment of chronic idiopathic constipation.